Skip to main content

Coronavirus: Molnupiravir

Question for Department of Health and Social Care

UIN 100629, tabled on 10 January 2022

To ask the Secretary of State for Health and Social Care, when the NHS plans to offer molnupiravir to covid-19 patients who are not taking part in clinical trials.

Answered on

18 January 2022

From 16 December 2021, molnupiravir was made available to a small group of patients as a second line treatment to neutralising monoclonal antibodies through COVID Medicines Delivery Units (CMDUs). In England, 1.3 million of the highest risk patients are eligible for treatments including molnupiravir through CMDUs. This includes patients at highest risk of hospitalisation and deterioration following COVID-19 infection. Should they receive a positive polymerase chain reaction test, they will be assessed by clinicians and offered antiviral or antibody treatments from a CMDU, if eligible.

The PANORAMIC national study has been established to produce conclusive data on those who would benefit from antiviral treatments for COVID-19. We will use this data to consider how to make antivirals available more widely in the United Kingdom.